Related Experiment Video

Updated: Jun 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Dynamics of NRTI resistance mutations during therapy interruption

Maria Trignetti1, Tobias Sing, Valentina Svicher

  • 1Experimental Medicine Department, University of Rome Tor Vergata , 00133, Rome, Italy.

AIDS Research and Human Retroviruses
|February 3, 2009
PubMed

Insights

Drug resistance mutations in nucleoside analogue reverse transcriptase inhibitors (NRTIs) are lost at varying rates during treatment interruption (TI). These mutations, like K65R and M184I/V, disappear rapidly and independently, impacting viral fitness.

Area of Science:

  • Virology
  • Pharmacology
  • Epidemiology

Background:

  • Limited data exists on the evolution of drug resistance mutations during treatment interruption (TI).
  • Understanding mutation dynamics during TI is crucial for managing antiviral therapy and treatment strategies.

Purpose of the Study:

  • To investigate the dynamics of nucleoside analogue reverse transcriptase inhibitor (NRTI) resistance mutations during TI.
  • To determine the rates and patterns of NRTI resistance mutation loss during TI.

Main Methods:

  • Survival analysis approach was used.
  • Analysis included 132 patients with at least two consecutive genotypes, including one at regimen failure and one during TI.
  • Rates of disappearance for individual NRTI resistance mutations were assessed.

Main Results:

  • NRTI resistance mutations disappear at different rates during TI and are mostly lost independently.
  • K65R and M184I/V mutations were rapidly lost in most patients, associated with wild-type virus reemergence.
  • The loss of NRTI resistance mutations during TI is not an ordered process and occurs without significant interaction among mutations in most cases.

Conclusions:

  • The loss of NRTI resistance mutations during TI is a complex, non-ordered process.
  • Rapid disappearance of K65R and M184I/V suggests a negative impact on viral fitness.
  • Findings provide insights into the evolutionary dynamics of drug resistance during TI.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.